Skip to main content
L

LTR PHARMA LIMITED — Investor Relations & Filings

Ticker · LTP ISIN · AU0000305294 ASX Manufacturing
Filings indexed 127 across all filing types
Latest filing 2025-05-20 Regulatory Filings
Country AU Australia
Listing ASX LTP

About LTR PHARMA LIMITED

https://ltrpharma.com

LTR Pharma Limited focuses on the development and commercialization of innovative therapies for men’s health. The company’s lead product candidate, SPONTAN, is a proprietary nasal spray formulation of vardenafil designed for the treatment of erectile dysfunction. Utilizing a unique delivery platform, SPONTAN is engineered to provide a significantly faster onset of action compared to traditional oral medications. By leveraging advanced drug delivery technology to bypass first-pass metabolism, the formulation aims to improve patient outcomes and reduce the time to efficacy. LTR Pharma is dedicated to advancing its clinical programs through regulatory pathways to provide rapid-acting solutions for men’s health conditions.

Recent filings

Filing Released Lang Actions
Urological Expert Appointed to LTR Scientific Advisory Board 3 pages 142.1KB
Regulatory Filings
2025-05-20 English
SPONTAN Expands Patient Access via National Pharmacy Network 3 pages 142.5KB
Regulatory Filings
2025-05-19 English
LTR Signs Collaborative Agreement to Develop OMD Nasal Spray 3 pages 173.4KB
Regulatory Filings
2025-05-07 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 474.1KB
Regulatory Filings
2025-04-28 English
Change of Registered Office Address 1 page 118.8KB
Regulatory Filings
2025-04-03 English
Change of Company Secretary 1 page 119.5KB
Regulatory Filings
2025-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.